Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up
Piamsomboon, C.; Laothavorn, P.; Chatlaong, B.; Saguanwong, S.; Nasawadi, C.; Tanprasert, P.; Leelaprute, M.; Intayakorn, U.; Amornsak, N.
Journal of the Medical Association of Thailand 84(12): 1701-1707
2001
ISSN/ISBN: 0125-2208 PMID: 11999816 Document Number: 6640
Clopidogrel is a new thienopyridine derivative and has less serious hematologic complications. We investigated the efficacy of clopidogrel plus aspirin (CA) in stent thrombosis prevention compared with ticlopidine plus aspirin (TA). Sixty-eight patients who underwent coronary stenting were randomized into 2 groups: TA group, n = 31 and CA group, n = 37. At 1 month, there were 3 major bleeding complications, 2 in the CA group and 1 in the TA group. Neither stent thrombosis nor hematologic events were found in both groups. Two patients in the TA group died, 1 from sudden death and another from tracheal stenosis. At 6 months, five patients developed in-stent restenosis, 4 in the CA group and 1 in the TA group, p = NS. One patient in each group had acute coronary syndrome. Clopidogrel plus aspirin is an effective coronary stenting regimen comparable to ticlopidine plus aspirin.
Document emailed within 1 workday
